Mutations in the 23S rRNA gene of clarithromycin-resistant Helicobacter pylori from Japan

被引:27
作者
Rimbara, Emiko
Noguchi, Norihisa
Kijima, Hidenobu
Yamaguchi, Tai
Kawai, Takashi
Sasatsu, Masanori
机构
[1] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Microbiol, Hachioji, Tokyo 1920392, Japan
[2] Tokyo Med Univ, Endoscopy Ctr, Shinjuku Ku, Tokyo 1600023, Japan
关键词
Helicobacter pylori; clarithromycin; antimicrobial resistance; 23S rRNA;
D O I
10.1016/j.ijantimicag.2007.04.009
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
The 23S rRNA gene in clinical isolates of Helicobacter pylori isolated between 1995 and 2004 from Japan was investigated and the relationship between mutations in this gene and clarithromycin susceptibility was studied. Among nine mutations that have previously been reported to confer clarithromycin resistance, an adenine -> guanine transition at position 2142 (A2142G) or 2143 (A2143G) was detected in all clarithromycin-resistant strains (n = 67) but not in any clarithromycin-susceptible strains (n = 17). Mutations at positions 2182, 2223, 2244 and 2288 have previously been reported to confer clarithromycin resistance in H. pylori isolates from Bangladesh, China and Brazil. However, these mutations were not associated with clarithromycin resistance in H. pylori isolates from Japan in this study. Other mutations at positions 2115, 2144 and 2711, which have also been reported to confer clarithromycin resistance in H. pylori from Sweden and Italy, were not detected in the strains in this study. Our results suggest that susceptibility to clarithromycin is predicted by detection of mutations at positions 2142 and 2143 of the 23S rRNA gene in H. pylori isolates in Japan. (C) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:250 / 254
页数:5
相关论文
共 15 条
[1]
[Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1
[2]
Guidelines in the management of Helicobacter pylori infection in Japan [J].
Asaka, M ;
Satoh, K ;
Sugano, K ;
Sugiyama, T ;
Takahashi, S ;
Fukuda, Y ;
Ota, H ;
Murakami, K ;
Kimura, K ;
Shimoyama, T .
HELICOBACTER, 2001, 6 (03) :177-186
[3]
Risk factors for failure of Helicobacter pylori therapy -: results of an individual data analysis of 2751 patients [J].
Broutet, N ;
Tchamgoué, S ;
Pereira, E ;
Lamouliatte, H ;
Salamon, R ;
Mégraud, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (01) :99-109
[4]
*CLIN LAB STAND I, 2002, M100S12 CLIN LAB STA
[5]
New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates [J].
Fontana, C ;
Favaro, M ;
Minelli, S ;
Criscuolo, AA ;
Pietroiusti, A ;
Galante, A ;
Favalli, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) :3765-3769
[6]
Hao Q, 2004, WORLD J GASTROENTERO, V10, P1075
[7]
Macrolide resistance in Helicobacter pylori: Mechanism and stability in strains from clarithromycin-treated patients [J].
Hulten, K ;
Gibreel, A ;
Skold, O ;
Engstrand, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2550-2553
[8]
T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh [J].
Khan, R ;
Nahar, S ;
Sultana, J ;
Ahmad, MM ;
Rahman, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3567-3569
[9]
Ribeiro Marcelo L, 2003, Ann Clin Microbiol Antimicrob, V2, P11
[10]
Development of a highly sensitive method for detection of clarithromycin-resistant Helicobacter pylori from human feces [J].
Rimbara, E ;
Noguchi, N ;
Yamaguchi, T ;
Narui, K ;
Kawai, T ;
Sasatsu, M .
CURRENT MICROBIOLOGY, 2005, 51 (01) :1-5